A pragmatic trial to evaluate the intermediate-term effects of early aggressive versus escalation therapy in people with multiple sclerosis

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Multiple Sclerosis
  • Age: Between 18 - 60 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Subjects who are between 18 and 60 years of age
    2. Subjects who meets 2017 McDonald criteria for relapsing remitting MS
    3. Subjects who must be EITHER JC virus antibody negative or low positive (index antibody titer <0.9), OR negative for: Hepatitis B and C, tuberculosis
    4. Subjects who are HIV negative
    5. Subjects who have no chemotherapy in past year

You may not be eligible for this study if the following are true:

    1. Subjects with prior treatment with rituximab, ocrelizumab, alemtuzumab, mitoxantrone or cladribine
    2. Subjects with prior treatment with any other MS DMT for more than 6 months
    3. Subjects who have a progressive neurological disorder
    4. Subjects with prior treatment with experimental aggressive therapies
    5. Subjects with treatment with teriflunomide within past 2 years
    6. Subjects who had treatment in the past 6 months with any MS DMT
    7. Subjects with prior treatment with any other investigational immune-modulating/suppressing drug for MS not listed above
    8. Subjects who are pregnant or breast-feeding.
    9. Female subjects of child-bearing age who are planning or strongly considering conception during the study time frame



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.